These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29882690)

  • 1. Immunotherapy combinations emerging in non-small-cell lung cancer.
    Chao YL; Pecot CV
    Immunotherapy; 2018 Jun; 10(8):627-629. PubMed ID: 29882690
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
    Santana-Davila R; Chow LQ
    Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
    Uprety D
    Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
    Gkolfinopoulos S; Mountzios G
    Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice].
    Wang ZM; Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):95-99. PubMed ID: 32062879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A banner year for immunotherapy and targeted therapy.
    Carlisle JW; Ramalingam SS
    Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
    [No Abstract]   [Full Text] [Related]  

  • 8. The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
    Rocco D; Gravara LD; Gridelli C
    Curr Clin Pharmacol; 2020; 15(1):11-19. PubMed ID: 31400270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
    Dong J; Li B; Zhou Q; Huang D
    J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].
    Simonneau Y; Ruppert AM; Chaabane N; Lavolé A; Wislez M
    Bull Cancer; 2018 Oct; 105(10):854-856. PubMed ID: 30262415
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
    Puri S; Chatwal M; Gray JE
    Expert Rev Respir Med; 2017 Oct; 11(10):791-805. PubMed ID: 28786318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer.
    Stiles BM; Sepesi B; Broderick SR; Bott MJ
    J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1376-1382. PubMed ID: 32763029
    [No Abstract]   [Full Text] [Related]  

  • 13. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for non-small cell lung cancer.
    Vafadar S
    JAAPA; 2019 Sep; 32(9):37-42. PubMed ID: 31460972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-small cell lung cancer].
    Skřičková J; Kadlec B; Venclíček O
    Vnitr Lek; 2018; 63(11):861-874. PubMed ID: 29303290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update.
    Abdel-Rahman O; Morris D
    Immunotherapy; 2019 Feb; 11(3):149-153. PubMed ID: 30730273
    [No Abstract]   [Full Text] [Related]  

  • 17. The Lingering Questions in Immunotherapy.
    Wright K
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212135
    [No Abstract]   [Full Text] [Related]  

  • 18. NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
    Gubens MA; Davies M
    J Natl Compr Canc Netw; 2019 May; 17(5.5):574-578. PubMed ID: 31117034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of N2 non-small cell lung cancer (NSCLC).
    Klastersky J; Feld R; Kleisbauer JP; Rocmans P
    Chest; 1989 Jul; 96(1 Suppl):83S-85S. PubMed ID: 2544376
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC.
    Benitez JC; Mezquita L; Colle R; Tselikas L; Botticella A; Caramella C; Besse B
    J Thorac Oncol; 2019 Oct; 14(10):e215-e216. PubMed ID: 31302233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.